Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer

Evaluating risk factors for Trastuzumab-Deruxtecan Pneumonitis in patients with metastatic breast cancer

Abstract Background Trastuzumab deruxtecan (T-DXd) is FDA-approved for treatment of patients with HER2 positive and HER2-low metastatic breast cancer. Currently, there is limited understanding of pre-treatment risk factors for pneumonitis associated with T-DXd. Methods Consecutive breast cancer pati...

Full description

Saved in:
Bibliographic Details
Main Authors: Jonathan Henricks, Tyler Haddad, Omair Ahmed, Jonathan Schoenhals, Pavnesh Kumar, Ryan Wilson, Jianing Ma, Jing Gennie Wang, Michael Wert, Vincent Esguerra, Ian Bentley, Kai Johnson, Daniel Stover, Sachin R. Jhawar, Margaret Gatti-Mays, Kevin Ho
Format: Article
Language:English
Published: BMC 2025-02-01
Series:Breast Cancer Research
Subjects:
Trastuzumab-Deruxtecan
Pneumonitis
Breast cancer
Online Access:https://doi.org/10.1186/s13058-025-01967-1
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items